Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort

MLA

Ta-Wei Liu, et al. “Identification of Treatment-Experienced Hepatitis C Patients with Poor Cost-Effectiveness of Pegylated Interferon plus Ribavirin from a Real-World Cohort.” Journal of the Formosan Medical Association, vol. 117, no. 1, Jan. 2018, pp. 54–62. EBSCOhost, https://doi.org/10.1016/j.jfma.2017.02.013.

APA

Ta-Wei Liu, Pei-Chien Tsai, Ching-I Huang, Yi-Shan Tsai, Shu-Chi Wang, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Nai-Jen Hou, Chung-Feng Huang, Ming-Lun Yeh, Zu-Yau Lin, Shinn-Cherng Chen, Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, & Ming-Lung Yu. (2018). Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. Journal of the Formosan Medical Association, 117(1), 54–62. https://doi.org/10.1016/j.jfma.2017.02.013

Chicago

Ta-Wei Liu, Pei-Chien Tsai, Ching-I Huang, Yi-Shan Tsai, Shu-Chi Wang, Yu-Min Ko, Ching-Chih Lin, et al. 2018. “Identification of Treatment-Experienced Hepatitis C Patients with Poor Cost-Effectiveness of Pegylated Interferon plus Ribavirin from a Real-World Cohort.” Journal of the Formosan Medical Association 117 (1): 54–62. doi:10.1016/j.jfma.2017.02.013.